4Q23 results included charges related to the Daiichi Sankyo collaboration .

The analyst lowered expectations for Januvia, Bridion ... a 4% increase in third-quarter revenue for 2024, reaching $16.7 billion, driven by strong sales of its cancer drug KEYTRUDA and the ...

The S&P 500 added 0.7% on Tuesday, Feb. 4, as investors evaluated developments on U.S. tariffs, labor market data, and the latest earnings news.

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

President Joe Biden attends the Department of Defense Commander in Chief farewell ceremony at Joint Base Myer-Henderson Hall, Thursday, Jan. 16, 2025, in Arlington, Va. (AP Photo/Evan Vucci ...

We took NCEs first launched between 2004 and 2011, analysing 16 countries accounting for almost ... 2 Of the 10 identified, only one, Januvia, is a conventionally primary care launch.

AstraZeneca), sitagliptin (Januvia; Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...